Mitsubishi UFJ Asset Management Co. Ltd. Takes $126.12 Million Position in Edwards Lifesciences Corporation $EW

Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in shares of Edwards Lifesciences Corporation (NYSE:EW) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 1,394,217 shares of the medical research company’s stock, valued at approximately $126,121,000. Mitsubishi UFJ Asset Management Co. Ltd. owned about 0.24% of Edwards Lifesciences as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of EW. Bank of New York Mellon Corp bought a new position in Edwards Lifesciences in the 2nd quarter valued at about $1,274,082,000. Norges Bank acquired a new position in shares of Edwards Lifesciences in the fourth quarter valued at approximately $803,686,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Edwards Lifesciences by 278.3% in the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock valued at $434,318,000 after purchasing an additional 4,108,270 shares during the last quarter. Viking Global Investors LP acquired a new position in shares of Edwards Lifesciences in the third quarter valued at approximately $238,688,000. Finally, Marshall Wace LLP increased its stake in shares of Edwards Lifesciences by 66.1% during the fourth quarter. Marshall Wace LLP now owns 5,925,627 shares of the medical research company’s stock worth $505,160,000 after purchasing an additional 2,359,128 shares during the period. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Up 0.4%

NYSE EW opened at $91.13 on Wednesday. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 1-year low of $72.30 and a 1-year high of $96.29. The company has a 50 day moving average of $88.90 and a 200-day moving average of $84.49. The company has a market cap of $52.47 billion, a price-to-earnings ratio of 52.37, a PEG ratio of 2.30 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The business had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.70 billion. During the same quarter in the prior year, the business posted $0.67 earnings per share. The firm’s quarterly revenue was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, equities research analysts expect that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Insider Activity

In related news, SVP Andrew M. Dahl sold 568 shares of the business’s stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $86.08, for a total value of $48,893.44. Following the completion of the transaction, the senior vice president owned 15,334 shares of the company’s stock, valued at $1,319,950.72. The trade was a 3.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the business’s stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total value of $2,000,190.90. Following the completion of the transaction, the vice president directly owned 98,611 shares of the company’s stock, valued at approximately $8,521,962.62. This trade represents a 19.01% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 25,570 shares of company stock worth $2,219,390. 0.31% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several analysts recently weighed in on EW shares. BTIG Research lifted their price target on Edwards Lifesciences from $100.00 to $110.00 and gave the stock a “buy” rating in a report on Tuesday, June 30th. Royal Bank Of Canada upped their price objective on Edwards Lifesciences from $100.00 to $110.00 and gave the company an “outperform” rating in a report on Monday, July 13th. Citigroup increased their price objective on Edwards Lifesciences from $101.00 to $110.00 and gave the stock a “buy” rating in a research report on Wednesday, July 8th. UBS Group began coverage on Edwards Lifesciences in a report on Tuesday, July 28th. They set a “buy” rating and a $110.00 target price for the company. Finally, Mizuho boosted their target price on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the company an “outperform” rating in a research report on Wednesday, July 15th. Seventeen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat, Edwards Lifesciences presently has an average rating of “Moderate Buy” and an average target price of $100.27.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.